Profectus Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Profectus Biosciences's estimated annual revenue is currently $1.2M per year.
- Profectus Biosciences's estimated revenue per employee is $77,500
- Profectus Biosciences's total funding is $34.7M.
Employee Data
- Profectus Biosciences has 16 Employees.
- Profectus Biosciences grew their employee count by -6% last year.
Profectus Biosciences's People
| Name | Title | Email/Phone |
|---|
Profectus Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is Profectus Biosciences?
Its creation fulfills a promise to the state that the institute would spin off a bioscience business to foster economic and societal growth in Maryland. Profectus is at a University of Maryland business incubator in College Park.
keywords:N/A
$34.7M
Total Funding
16
Number of Employees
$1.2M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Profectus Biosciences News
Merck; Advaxis Immunotherapies; Bionor Pharma; Dendreon Corporation; Inovio Pharmaceuticals; ISA Pharmaceuticals; Otsuka Pharmaceuticals; Profectus Biosciences...
Profectus BioSciences Inc; Rodos BioTarget GmbH; Sarepta Therapeutics Inc; Theravectys SA. Our delegates have endeavoured to stay aware of the most raised...
... Bionor Pharma, Dendreon Corporation, Inovio Pharmaceuticals, ISA Pharmaceuticals, Otsuka Pharmaceuticals, Profectus Biosciences.
Other Companies in Baltimore
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.5M | 16 | 0% | N/A |
#2 | $2.4M | 16 | -11% | N/A |
#3 | $4M | 16 | 7% | N/A |
#4 | $4M | 16 | 7% | N/A |
#5 | $1.4M | 16 | 7% | N/A |